CausalSentinel

Protein Dossier — FGFR3 (Fibroblast growth factor receptor 3)

MR feasibility tier: A — Published pQTL-MR estimates exist for this protein (retrieved below - not computed here).

1. Published MR estimates (retrieved, not computed)

Outcome beta se p method nSNP cis/trans coloc
Non-cancer illness code self-reported: hypopituitarism 1.2 0.271 8.83e-06 Wald ratio 1 cis NA
Non-cancer illness code self-reported: osteoarthritis 0.114 0.0456 0.0121 Wald ratio 1 cis NA
Cancer code self-reported: prostate cancer 0.325 0.132 0.0136 Wald ratio 1 cis NA
Diagnoses - main ICD10: C61 Malignant neoplasm of prostate 0.328 0.138 0.0171 Wald ratio 1 cis NA
Diagnoses - main ICD10: G56 Mononeuropathies of upper limb 0.213 0.0947 0.0246 Wald ratio 1 cis NA
Diagnoses - main ICD10: M16 Coxarthrosis [arthrosis of hip] -0.456 0.211 0.031 Wald ratio 1 cis NA
ER-negative Breast cancer (Combined Oncoarray; iCOGS; GWAS meta analysis) -0.154 0.0723 0.0329 Wald ratio 1 cis NA
Diagnoses - main ICD10: N40 Hyperplasia of prostate 0.26 0.125 0.0372 Wald ratio 1 cis NA
Alcohol intake frequency -0.0465 0.0225 0.0388 Wald ratio 1 cis NA
Pulse rate -0.0532 0.027 0.0485 Wald ratio 1 cis NA
Diagnoses - main ICD10: R35 Polyuria 0.347 0.179 0.053 Wald ratio 1 cis NA
Intracranial volume 2.59e+04 1.4e+04 0.0648 Wald ratio 1 cis NA
…and 53 more outcomes (see JSON)              

2. pQTL instrument availability (Tier-B probe)

Dataset Trait Author Year
prot-c-3809_1_2 FGFR-3 Suhre K 2019

3. GWAS Catalog results — traits with signal at this locus

110 association rows across 65 traits (102 genome-wide significant rows). Associations are loci, not causal claims; the mapped gene at a locus is not necessarily the effector gene.

Trait best p lead SNP n assoc study MR status
Height 4e-63 rs1867926 11 GCST90245848 no MR -> candidate analysis
Type 2 diabetes 4e-55 rs6831006 14 GCST90492734 MR: beta=-0.234, p=0.384 (cis)
Vertex-wise sulcal depth 9e-48 rs11724531 1 GCST90095129 no MR -> candidate analysis
Standing height (UKB data field 50) 9e-43 rs11731421 2 GCST90468178 no MR -> candidate analysis
Height (baseline) 8e-36 rs11731421 5 GCST90565843 no MR -> candidate analysis
Osteoarthritis (with total knee replacement) 2e-32 rs11731421 2 GCST90566805 no MR -> candidate analysis
Knee osteoarthritis 2e-32 rs11731421 2 GCST90566800 no MR -> candidate analysis
Osteoarthritis 4e-28 rs12509303 2 GCST90566795 MR: beta=0.114, p=0.0121 (cis)
Type 2 diabetes (PheCode 250.2) 4e-26 rs56337234 2 GCST90475667 no MR -> candidate analysis
Diabetes mellitus (PheCode 250) 1e-25 rs56337234 1 GCST90475658 no MR -> candidate analysis
Vertex-wise cortical surface area 2e-25 rs13142863 1 GCST90095130 no MR -> candidate analysis
Osteoarthritis of the hip or knee 3e-25 rs12509303 1 GCST90566799 no MR -> candidate analysis
…and 53 more traits (see JSON)          

4. Phenome map — where this gene is a genetic locus, vs. where MR exists

Top diseases by Open Targets association (of 5225 total). Associations are loci, not causal claims. The causal-status column is a four-state triage per pair: established (curated) = a curated clinical assertion exists (ClinGen/G2P/GEL/Orphanet/ClinVar — any validity level, MR adds little); exploratory rare-variant signal = ExWAS burden evidence without curation — a candidate NEW gene-disease relationship; common-variant locus = GWAS signal, classic pQTL-MR territory; multi-layer = burden+GWAS together, an allelic-series candidate (the strongest causal setup). Burden estimand is carrier-vs-noncarrier, not per-SD MR.

Disease genetic assoc. burden (ExWAS) causal status MR status
achondroplasia 0.894 established (curated) no MR -> candidate analysis
thanatophoric dysplasia type 1 0.9 established (curated) no MR -> candidate analysis
Severe achondroplasia - developmental delay - acanthosis nigricans 0.892 established (curated) no MR -> candidate analysis
urinary bladder carcinoma 0.865 established (curated) no MR -> candidate analysis
hypochondroplasia 0.869 established (curated) no MR -> candidate analysis
Muenke syndrome 0.836 established (curated) no MR -> candidate analysis
urinary bladder cancer 0.831 established (curated) no MR -> candidate analysis
thanatophoric dysplasia type 2 0.835 established (curated) no MR -> candidate analysis
Crouzon syndrome-acanthosis nigricans syndrome 0.853 established (curated) no MR -> candidate analysis
camptodactyly-tall stature-scoliosis-hearing loss syndrome 0.853 established (curated) no MR -> candidate analysis
thanatophoric dysplasia 0.762 established (curated) no MR -> candidate analysis
Crouzon syndrome - acanthosis nigricans 0.608 established (curated) no MR -> candidate analysis
seborrheic keratosis 0.842 established (curated) no MR -> candidate analysis
nevus, epidermal 0.904 established (curated) no MR -> candidate analysis
Camptodactyly - tall stature - scoliosis - hearing loss 0.608 established (curated) no MR -> candidate analysis

Of the 15 rows above, 15 have no MR estimate in this resource. Across all retrieved diseases for this gene: 0 exploratory rare-variant signal(s), 0 multi-layer (allelic-series candidate) pair(s). Final triage still belongs to a statistical geneticist.

5. Downstream annotation (druggability & safety preview)

Layer Result
ChEMBL druggability 9 known modulators (Fibroblast growth factor receptor 3)
gnomAD constraint pLI=1, LOEUF=0.421 — LoF-INTOLERANT
GWAS Catalog 85 unique SNPs / 170 rows
ClinVar 1472 records; 9 pathogenic in sample of 30
PharmGKB/ClinPGx no annotations

Caveats declared by the tools

Sources

Provenance